My Cart

TNFR2

TNFR2 Overview

English NameTumor necrosis factor receptor superfamily member 1BApproved Drugs1
Drugs in Clinical Trials8Target SynonymTNFR-II,TNFR80,TNF-RII,p80 TNF-alpha receptor,p75,Tumor necrosis factor receptor 2,Etanercept,TBP-2,Tumor necrosis factor receptor type II,TBPII,CD120b,TNF-R-II,CD120b Antigen,Tumor Necrosis Factor Beta Receptor,Soluble TNFR1B Variant 1,Tumor Necrosis Factor Binding Protein 2,TNFBR,TNF Receptor Superfamily Member 1B,TNFR2,P75 TNF Receptor,P75TNFR,TNFR1B,Tumor Necrosis Factor Receptor Superfamily, Member 1B,TNF-R75,TNF-R2
Highest Development StageApproved
English NameTumor necrosis factor receptor superfamily member 1B
Target SynonymTNFR-II,TNFR80,TNF-RII,p80 TNF-alpha receptor,p75,Tumor necrosis factor receptor 2,Etanercept,TBP-2,Tumor necrosis factor receptor type II,TBPII,CD120b,TNF-R-II,CD120b Antigen,Tumor Necrosis Factor Beta Receptor,Soluble TNFR1B Variant 1,Tumor Necrosis Factor Binding Protein 2,TNFBR,TNF Receptor Superfamily Member 1B,TNFR2,P75 TNF Receptor,P75TNFR,TNFR1B,Tumor Necrosis Factor Receptor Superfamily, Member 1B,TNF-R75,TNF-R2
Approved Drugs1
Drugs in Clinical Trials8
Highest Development StageApproved

TNFR2 Background

TNFR2 (tumor necrosis factor receptor superfamily member 1B) is a receptor with high affinity for TNFSF2/TNF-alpha. It has a much lower affinity for homotrimeric TNFSF1/lymphotoxin-alpha. The TRAF1/TRAF2 complex recruits the apoptotic suppressors BIRC2 and BIRC3 to TNFRSF1B/TNFR2. TNFR2 mediates most of the metabolic effects of TNF-alpha.

TNFR2 Synonyms

TNFRSF1B,CD120b,TBPII,TNF-R-II,TNF-R75,TNFBR,TNFR1B,TNFR2,TNFR80,p75,p75TNFR

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
LBL-019LBL-019Phase 2 ClinicalNanjing Leadsbiolabs Co LtdNeoplasms
Details
BI-1910BI-1910Phase 2 ClinicalBioinvent International AbCarcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Solid tumours
Details
BITR-2101BITR-2101; BIR-2101; BITT2101; BITT-2101Phase 1 ClinicalBoston Immune Technologies & TherapeuticsInfections; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Neoplasms
Details
TRB-061TRB-061Phase 1 ClinicalTrex Bio IncColitis; Dermatitis; Dermatitis, Atopic
Details
NBL-020Phase 1 ClinicalShanghai Xinshi Biological Medicine Co LtdNeoplasms; Solid tumours
Details
BC-011BC-011Phase 1 ClinicalDragonboat BiopharmaceuticalSolid tumours
Details
SIM1811-03SIM1811-03; SIM0235; SIM-235Phase 1 ClinicalJiangsu Simcere Pharmaceutical Co LtdLymphoma, T-Cell, Cutaneous; Neoplasms; Solid tumours
Details
EmunkitugHFB-2003; HFB-200301Phase 1 ClinicalHiFiBiO TherapeuticsCarcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Germinoma; Melanoma; Mesothelioma; Neoplasm Metastasis; Neoplasms; Sarcoma; Skin Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Testicular Neoplasms; Uterine Cervical Neoplasms
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
Recombinant human type II tumor necrosis factor receptor-antibody fusion protein(Hisun Biological)ApprovedHisun Biopharmaceutical Co LtdMainland ChinaSpondylitis, Ankylosing; Psoriasis; Arthritis, RheumatoidHisun Biopharmaceutical Co Ltd2015-04-09Arthritis, Rheumatoid; Psoriasis; Spondylitis, Ankylosing
Details
  • Overview
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information